Literature DB >> 17885560

Association of depressed cardiac gp130-mediated antiapoptotic pathways with stimulated cardiomyocyte apoptosis in hypertensive patients with heart failure.

Arantxa González1, Susana Ravassa, Iñigo Loperena, Begoña López, Javier Beaumont, Ramón Querejeta, Mariano Larman, Javier Díez.   

Abstract

OBJECTIVE: To investigate whether the glycoprotein (gp130)-mediated survival pathway, which protects cardiomyocytes from apoptosis, is depressed in left ventricular hypertrophy hypertensive patients with chronic heart failure.
METHODS: Transvenous endomyocardial biopsies were obtained in 52 hypertensive patients with left ventricular hypertrophy: 28 without heart failure and 24 with heart failure. gp130 and gp130-dependent antiapoptotic pathways p42/44 mitogen-activated protein kinase (MAPK) and phosphatidylinositol-3 kinase (PI3K)/protein kinase B (Akt) as well as gp130 agonist cardiotrophin-1 were analyzed by reverse transcriptase-polymerase chain reaction and western blot. Apoptosis was assessed by DNA end-labeling (TUNEL), caspase-3 immunostaining and caspase substrate poly(ADP-ribose) polymerase cleavage.
RESULTS: gp130 protein expression (P < 0.05) and p42/44 MAPK and PI3K/Akt activation (P < 0.01) were decreased in heart-failure hypertensive patients compared with nonheart-failure hypertensive individuals. No changes in gp130 mRNA expression were found between the two groups. Cardiotrophin-1 was increased (P < 0.05) at both the mRNA and protein levels in heart-failure hypertensive individuals compared with nonheart-failure hypertensive individuals. Cardiomyocyte apoptosis was increased (P < 0.01) in heart-failure hypertensive individuals compared with nonheart-failure hypertensive individuals. Inverse correlations (P < 0.01) occurred between cardiomyocyte apoptosis and p42/44 MAPK and PI3K/Akt activation in all hypertensive patients. Cardiotrophin-1 correlated inversely (r = -0.554, P < 0.05) with gp130 in all hypertensive individuals. In cultured HL-1 cardiomyocytes, cardiotrophin-1 decreased (P < 0.05) the gp130:phosphorylated gp130 (at Ser782) ratio and increased (P < 0.05) gp130ubiquitination.
CONCLUSIONS: An association exists between depression of the gp130 cytoprotective pathway and stimulation of cardiomyocyte apoptosis in hypertensive patients that develop heart failure. Whether the excess of cardiotrophin-1 induces ligand-induced receptor down-regulation in these patients requires further study.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17885560     DOI: 10.1097/HJH.0b013e32828626e2

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  16 in total

Review 1.  Myocardial AKT: the omnipresent nexus.

Authors:  Mark A Sussman; Mirko Völkers; Kimberlee Fischer; Brandi Bailey; Christopher T Cottage; Shabana Din; Natalie Gude; Daniele Avitabile; Roberto Alvarez; Balaji Sundararaman; Pearl Quijada; Matt Mason; Mathias H Konstandin; Amy Malhowski; Zhaokang Cheng; Mohsin Khan; Michael McGregor
Journal:  Physiol Rev       Date:  2011-07       Impact factor: 37.312

2.  Calcimimetic R568 improved cardiac remodeling by classic and novel renin-angiotensin system in spontaneously hypertensive rats.

Authors:  Tian Zhang; Na Tang; Dongmei Xi; Yongli Zhao; Yongmin Liu; Lamei Wang; Yan Tang; Xiaoni Zhang; Hua Zhong; Fang He
Journal:  Exp Biol Med (Maywood)       Date:  2019-06-03

3.  Mammalian target of rapamycin is a critical regulator of cardiac hypertrophy in spontaneously hypertensive rats.

Authors:  Will Soesanto; Han-Yi Lin; Eric Hu; Shane Lefler; Sheldon E Litwin; Sandra Sena; E Dale Abel; J David Symons; Thunder Jalili
Journal:  Hypertension       Date:  2009-11-02       Impact factor: 10.190

Review 4.  Circulating biomarkers in the early detection of hypertensive heart disease: usefulness in the developing world.

Authors:  Dike Ojji; Elena Libhaber; Kim Lamont; Friedrich Thienemann; Karen Sliwa
Journal:  Cardiovasc Diagn Ther       Date:  2020-04

5.  Cardiac-specific mutation of Clock alters the quantitative measurements of physical activities without changing behavioral circadian rhythms.

Authors:  Michael L Ko; Liheng Shi; Ju-Yun Tsai; Martin E Young; Nichole Neuendorff; David J Earnest; Gladys Y-P Ko
Journal:  J Biol Rhythms       Date:  2011-10       Impact factor: 3.182

6.  Circadian profiles in the embryonic chick heart: L-type voltage-gated calcium channels and signaling pathways.

Authors:  Michael L Ko; Liheng Shi; Kirill Grushin; Fikru Nigussie; Gladys Y-P Ko
Journal:  Chronobiol Int       Date:  2010-10       Impact factor: 2.877

Review 7.  Proteases in cardiometabolic diseases: Pathophysiology, molecular mechanisms and clinical applications.

Authors:  Yinan Hua; Sreejayan Nair
Journal:  Biochim Biophys Acta       Date:  2014-05-09

8.  Mitochondrial targeted peptides attenuate residual myocardial damage after reversal of experimental renovascular hypertension.

Authors:  Alfonso Eirin; Barbara J Williams; Behzad Ebrahimi; Xin Zhang; John A Crane; Amir Lerman; Stephen C Textor; Lilach O Lerman
Journal:  J Hypertens       Date:  2014-01       Impact factor: 4.844

Review 9.  JAK redux: a second look at the regulation and role of JAKs in the heart.

Authors:  Mazen Kurdi; George W Booz
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-08-28       Impact factor: 4.733

Review 10.  Plasma cardiotrophin-1 levels are associated with hypertensive heart disease: a meta-analysis.

Authors:  Kangxing Song; Shuxia Wang; Bihui Huang; Amelia Luciano; Roshni Srivastava; Arya Mani
Journal:  J Clin Hypertens (Greenwich)       Date:  2014-07-23       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.